Confirming the diagnosis of CIDP early is critical to preventing long-term disability. However, the rare demyelinating condition is often misdiagnosed. Mayo Clinic Laboratories offers a new test that builds upon the individual NF155 test to help physicians with early diagnosis and treatment optimization.

The new test detects two antibodies — NF155 and CNTN1 — that are known to cause about 10% to 20% of CIDP cases and require different treatment than other CIDP cases. It uses two assays that are more specific and sensitive than other methodologies.

For more information, listen to this “Test in Focus” episode of the “Answers From the Lab” podcast.